Watson Bio's 23-valent pneumonia vaccine makes its debut in the Latin American market.

On August 26th, according to information from Walvax Biotechnology, the 23-valent pneumococcal polysaccharide vaccine produced by Yuxi Walvax Biotechnology Co., Ltd., a subsidiary of Walvax Biotechnology Holdings, has recently completed its first export delivery to El Salvador. This marks the official entry of Walvax Biotechnology's vaccine products into the Latin American market. As the world's first 23-valent pneumococcal polysaccharide vaccine without preservatives, this product is suitable for children over 2 years old and adults at high risk. The global cumulative sales of this product have now exceeded 14 million doses.